CHD1 (Chromodomain Helicase DNA Binding Protein 1) is an ATP-dependent chromatin remodeler essential for regulating gene expression, maintaining genomic integrity, and orchestrating epigenetic programs in eukaryotes. As a member of the SNF2H family of chromatin remodelers, CHD1 uses the energy from ATP hydrolysis to slide, restructure, and evict nucleosomes, thereby facilitating transcription factor access to DNA and maintaining proper chromatin architecture. With a molecular weight of ~223 kDa and containing 2,074 amino acids, CHD1 is particularly critical in neurons where precise epigenetic regulation underlies synaptic plasticity, learning and memory, and neuronal survival[1].
CHD1 is distinguished by its two N-terminal chromodomains that specifically recognize methylated histone H3K4me3, targeting the protein to active promoter regions. The protein also contains SANT domains for histone tail binding and a central ATPase domain that performs nucleosome remodeling. CHD1 is essential for embryonic development, stem cell pluripotency, and neuronal function, making it a critical protein in both development and disease contexts.
| Property | Value |
|---|---|
| Protein Name | Chromodomain Helicase DNA Binding Protein 1 |
| Gene | CHD1 |
| UniProt ID | Q86W28 |
| PDB ID | 5O9G, 6BP5 |
| Molecular Weight | ~223 kDa (2,074 aa) |
| Subcellular Localization | Nucleus |
| Protein Family | CHD (chromodomain helicase/ATPase) family |
| ATPase Activity | ~0.5 μmol/min/mg |
CHD1 contains several distinct functional domains:
[ CHD1/2 ]-[ SANT1 ]-[ SANT2 ]-[ SLIDE ]-[ ATPase/DExx ]-[ Helicase C ]
1-400 400-500 500-600 600-700 700-1300 1300-2074
Functional Domains:
| Domain | Position | Function |
|---|---|---|
| Chromodomain 1/2 | 1-400 | H3K4me3 recognition, targeting |
| SANT1/2 | 400-600 | Histone tail binding |
| SLIDE | 600-700 | DNA binding, substrate recognition |
| ATPase/DExx | 700-1300 | Nucleosome remodeling (ATP hydrolysis) |
| Helicase C | 1300-2074 | Regulatory domain |
The two N-terminal chromodomains are signature features of CHD1:
The central ATPase domain provides the mechanical work for remodeling:
SANT (Swi3, Ada2, N-CoR, TFIIIB) domains:
CHD1 exhibits ATP-dependent chromatin remodeling:
| Property | Value | Notes |
|---|---|---|
| ATPase activity | Basal: low; stimulated: high | Stimulated by nucleosomes |
| Nucleosome sliding | 20-50 bp/step | Directional repositioning |
| Remodeling speed | ~1 nucleosome/second | Processive activity |
| DNA binding affinity | Kd ~10 nM | Nucleosome substrate |
| Histone binding | H3 tail preference | H3K4me3 enhances |
CHD1 shows preference for:
CHD1 remodels chromatin through multiple mechanisms[2]:
Nucleosome Sliding:
Nucleosome Eviction:
Nucleosome Restructuring:
CHD1 is centrally involved in transcription[3]:
Promoter Clearance:
Elongation Control:
Alternative Splicing:
CHD1 plays critical roles in genomic maintenance[4]:
Nucleotide Excision Repair (NER):
Transcription-Coupled Repair (TCR):
Homologous Recombination:
CHD1 is essential for maintaining pluripotency[5]:
CHD1 in neurons is critical for neuronal function[6]:
Immediate-Early Gene Expression:
Learning and Memory:
CHD1 mutations are found in familial ALS[7]:
Pathogenic Mechanisms:
Genetic Evidence:
Therapeutic Implications:
CHD1 variants cause developmental disorders[8]:
Intellectual Disability:
Autism Spectrum Disorder:
Mechanism:
Emerging evidence for CHD1 in AD:
Transcriptional Dysregulation:
Therapeutic Potential:
CHD1 interacts with histone modifications:
| Modification | Interaction | Consequence |
|---|---|---|
| H3K4me3 | Direct binding | Targeting to active promoters |
| H3K27ac | Cooperative | Enhanced remodeling |
| H3K36me3 | Elongation coupling | Transcription fidelity |
| H3K9me3 | Repression | Heterochromatin exclusion |
CHD1 affects 3D genome architecture[9]:
Loop Extrusion:
Compartment Organization:
CHD1 functions in multi-protein complexes[10]:
CHD1 can be pharmacologically modulated:
Direct Targeting:
Indirect Approaches:
| Approach | Development Stage | Indication |
|---|---|---|
| ATPase inhibitors | Preclinical | Cancer, ALS |
| BET inhibitors | Clinical trials | Cancer, inflammation |
| HDAC inhibitors | FDA approved | Cancer, neurology |
| Gene therapy | Early research | Genetic correction |
Specificity:
Delivery:
In Vitro:
In Vivo:
CHD1 as Biomarker:
CHD1 interacts with:
| Component | Interaction Type | Functional Consequence |
|---|---|---|
| H3K4me3 | Direct binding | Targeting |
| RNAPII | Physical association | Transcription |
| p300/CBP | Co-activator complex | Histone acetylation |
| SAGA | Co-complex | Coactivation |
| PAF1 | Elongation complex | Transcription |
| RAD51 | DNA repair | Homologous recombination |
Kelley MW, et al. CHD1 and Chromatin Remodeling in Development and Disease. Journal of Neuroscience. 2019. ↩︎
Barozzi I, et al. CHD1 and the mechanics of transcription. Nature Reviews Molecular Cell Biology. 2014. ↩︎
Toma MA, et al. CHD1 in transcription elongation. Molecular Cell. 2008. ↩︎
Hersh D, et al. CHD1 in DNA damage response. Cell. 2014. ↩︎
Gaspar-Maia A, et al. CHD1 and pluripotency in stem cells. Nature Reviews Molecular Cell Biology. 2014. ↩︎
Simpson A, et al. CHD1 in learning and memory. Learning and Memory. 2016. ↩︎
Sathyanarayana A, et al. CHD1 Mutations in Amyotrophic Lateral Sclerosis. Neurology. 2017. ↩︎
Park D, et al. CHD1 mutations in neurodevelopment. Human Molecular Genetics. 2018. ↩︎
Levy D, et al. CHD1 and 3D genome organization. Genes and Development. 2017. ↩︎
Schneiderman J, et al. The CHD1 protein complex. Journal of Biological Chemistry. 2008. ↩︎